SG Americas Securities LLC Buys New Shares in Astria Therapeutics, Inc. (NASDAQ:ATXS)

SG Americas Securities LLC purchased a new position in Astria Therapeutics, Inc. (NASDAQ:ATXS) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 14,078 shares of the biotechnology company’s stock, valued at approximately $155,000.

Other hedge funds have also added to or reduced their stakes in the company. RA Capital Management L.P. bought a new stake in shares of Astria Therapeutics in the 1st quarter valued at about $62,115,000. Vanguard Group Inc. boosted its stake in shares of Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares during the period. Millennium Management LLC grew its holdings in shares of Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after purchasing an additional 218,518 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Astria Therapeutics by 15.4% in the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock worth $8,878,000 after purchasing an additional 130,000 shares during the last quarter. Finally, Artal Group S.A. purchased a new position in shares of Astria Therapeutics in the first quarter worth $12,445,000. 98.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Oppenheimer raised their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a report on Tuesday, August 13th. TD Cowen started coverage on Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Friday, September 27th. Finally, Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Astria Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Stock Performance

ATXS stock opened at $11.68 on Friday. Astria Therapeutics, Inc. has a fifty-two week low of $4.26 and a fifty-two week high of $16.90. The company has a market capitalization of $641.38 million, a price-to-earnings ratio of -5.03 and a beta of 0.71. The business’s 50 day moving average price is $11.55 and its two-hundred day moving average price is $10.49.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Sell-side analysts forecast that Astria Therapeutics, Inc. will post -1.72 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.